Journal of Clinical Investigation · 2009 · 200 citations · 46 references
Life SciencesCardiologyPhysiologyCell SignalingPathophysiologySignal TransductionBlood Pressure RegulationCardiac PhysiologyCardiovascular Molecular PhysiologyCardiovascular PathophysiologyCardiovascular PhysiologyG Protein-coupled Receptor SignalingCellular HypertrophyExercise-induced Cardiovascular ResponsesHypertension PathophysiologyPde5 InhibitorsPhosphodiesterase SignalingProtein Kinase G SignalingVascular Smooth Muscle DysfunctionVascular Smooth Muscle Regulation
The heart initially compensates for hypertension-mediated pressure overload by enhancing its contractile force and developing hypertrophy without dilation. Gq protein-coupled receptor pathways become activated and can depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce cardiac damage during such stimulation remain largely unknown. Here we have shown that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure overload, with increased myocardial Gq signaling, marked cardiac hypertrophy and failure, and early mortality. Swimming exercise, which is not accompanied by Gq activation, induced a normal cardiac response, while Rgs2 deletion in Galphaq-overexpressing hearts exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by cGMP-dependent protein kinase (PKG), suppressing Gq-stimulated vascular contraction. In normal mice, but not Rgs2-/- mice, PKG activation by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardiac hypertrophy, inhibiting Gq-coupled stimuli. Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both genotypes, but PKG plasma membrane translocation was more transient in Rgs2-/- myocytes than in controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early myocardial compensation to pressure overload and mediates the initial antihypertrophic and cardioprotective effects of PDE5 inhibitors.
46
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Jeffery D. Molkentin, Jianrong Lu, Christopher L. Antos et al. · Cell · 1998 · 2.6K citations · Full text
Junichi Sadoshima, Yuhui Xu, Henry S. Slayter et al. · Cell · 1993 · 1.4K citations